Cardiology
Advertisement
The CardioNerds in tandem with Dr. Clyde Yancy analyze a case of an 80-year-old man with heart failure.
Supine blood pressure is correlated with a higher risk of adverse CVD risk.
Coronary Sinus Reducer Demonstrates Long-Term Efficacy in Refractory Angina: Insights from REDUCER-I
The observational REDUCER-I study aims to evaluate the real-world safety and effectiveness of the coronary sinus reducer.
The CardioNerds and expert faculty Dr. Shelley Zieroth analyze a patient's heart failure classification.
Learn how wildfire smoke from western Canada in June 2023 correlated with cardiopulmonary disease burden in Maryland.
The FDA recently announced a first time proposed rule which would require the tobacco industry to lower nicotine levels.
Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.
The CardioNerds and expert faculty Dr. Mark Drazner assess a woman's heart failure status.
The possibility of DCBs to rescue side branches during provisional coronary bifurcation stenting is appealing.
A study shows that humans, mice exposed to long-wavelength red light have lower rates of blood clots that cause stroke.
The study used SEER data of nearly 20,000 cases.
Estimates show that 2.2 million new cases of T2D and 1.2 million new cases of CVD are associated with sugary beverages.
According to several studies, anti-obesity medications demonstrate cardiovascular benefits beyond weight loss alone.
The CardioNerds and Dr. Mark Drazner discuss the right heart failure device placement with an elderly patient.
The CardioNerds and expert faculty Dr. Biykem Bozkurt discuss a 63-year-old patient with hypertension and T2D.
An electrocardiography (ECG)–based artificial intelligence risk estimator can predict the development of hypertension.
Dr. Amit Goyal details the first-in-human study of the Magenta Elevate system.
The CardioNerds and colleagues review the differential diagnosis for peripartum cardiomyopathy.
A study shows how how advancements in diagnostic tools and treatments for ATTR-CM have improved risk profiles.
A recent post-hoc analysis of the ATTRibute-CM trial shows the potential for acoramidis in treating ATTR-CM.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.